TY - JOUR
T1 - Controversies in inflammatory bowel disease
T2 - exploring clinical dilemmas using Cochrane reviews
AU - East, James E.
AU - Boyapati, Ray K.
AU - Torres, Joana
AU - Parker, Claire E.
AU - MacDonald, John K.
AU - Chande, Nilesh
AU - Feagan, Brian G.
N1 - Funding Information:
From the *Translational Gastroenterology Unit and Oxford NIHR Biomedical Research Centre, Experimental Medicine Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom; †Department of Gastroenterology, Monash Health, Melbourne, Victoria, Australia; ‡Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Hospital Beatriz Ângelo, Gastroenterology Division, Loures, Portugal; §Robarts Clinical Trials Inc. London, Ontario, Canada; ¶Cochrane IBD Group, University of Western Ontario, London, Ontario, Canada; ‖Division of Gastroenterology, Department of Medicine, University of Western Ontario, London, Ontario, Canada; **Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada Conflicts of interest: JEE has received consulting fees from Lumendi and Boston Scientific and speaker fees from Olympus and Falk. RKB, JT, CEP, and JKM have no known conflicts of interest. NC has received consulting fees from AbbVie, Janssen, Lupin, Pfizer, and Takeda and speaker fees from AbbVie, Allegran, Shire, and Takeda. BGF has received grant/research support from AbbVie Inc., Amgen Inc., AstraZeneca/MedImmune Ltd., Atlantic Pharmaceuticals Ltd., Boehringer-Ingelheim, Celgene Corporation, Celltech, Genentech Inc/ Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline (GSK), Janssen Research & Development LLC., Pfizer Inc., Receptos Inc. / Celgene International, Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts Pharma AG and UCB; consulting fees from Abbott/AbbVie, Ablynx, Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc., Aptevo Therapeutics, Astra Zeneca, Atlantic Pharma, Avir Pharma, Baxter Healthcare Corp., Biogen Idec, Boehringer-Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/ Biogen, EnGene, Ferring Pharma, RocheGenentech, Galapagos, GiCare Pharma, Gilead, Given Imaging Inc., GSK, Inception IBD Inc, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestles, Nextbiotix, Novonordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Receptos, Roche/Genentech, Salix Pharma, Serano, Shire, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc., Takeda, Teva Pharma,
Funding Information:
Supported by: Dr. James East was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed in this manuscript are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Publisher Copyright:
© 2018 Crohn's & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2019/3
Y1 - 2019/3
N2 - A symposium organized by the Cochrane IBD Group and presented at the 2017 Digestive Disease Week annual meeting reviewed the recent literature on several controversial topics in inflammatory bowel disease (IBD) management including the efficacy of oral aminosalicylates for induction and maintenance of Crohn's disease (CD), the feasibility of drug withdrawal in patients with quiescent CD, and strategies for detecting colon cancer in patients with IBD. This article summarizes the data presented at that session.
AB - A symposium organized by the Cochrane IBD Group and presented at the 2017 Digestive Disease Week annual meeting reviewed the recent literature on several controversial topics in inflammatory bowel disease (IBD) management including the efficacy of oral aminosalicylates for induction and maintenance of Crohn's disease (CD), the feasibility of drug withdrawal in patients with quiescent CD, and strategies for detecting colon cancer in patients with IBD. This article summarizes the data presented at that session.
KW - Cancer detection
KW - Colonoscopy
KW - Crohn's disease
KW - Drug withdrawal
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85061970571&partnerID=8YFLogxK
U2 - 10.1093/ibd/izy268
DO - 10.1093/ibd/izy268
M3 - Review article
C2 - 30789982
AN - SCOPUS:85061970571
SN - 1078-0998
VL - 25
SP - 472
EP - 478
JO - Inflammatory Bowel Diseases
JF - Inflammatory Bowel Diseases
IS - 3
ER -
